ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,461 to 2,480 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI vs Non-Ellipta MITT: serious adverse events114 of 1,545

114 of 1,547

0.0 points

-1.8 to 1.9

3,092NCT03467425

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days After Spinal Surgery14 of 1,544

14 of 1,547

0.0 points

-0.7 to 0.7

3,091NCT02388165

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery25 of 1,544

23 of 1,547

0.1 points

-0.8 to 1.0

3,091NCT02388165

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 90 Days After Surgery24 of 1,544

22 of 1,547

0.1 points

-0.8 to 1.0

3,091NCT02388165

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Postoperative S. Aureus Blood Stream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery14 of 1,544

14 of 1,547

0.0 points

-0.7 to 0.7

3,091NCT02388165

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

Panitumumab vs Concomitant Administration of Panitumumab and Chemotherapy: serious adverse events614 of 1,254

747 of 1,831

8.2 points

4.6 to 11.7

3,085NCT02089737

Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

Etanercept vs Tocilizumab: serious adverse events422 of 1,542

479 of 1,538

-3.8 points

-7.0 to -0.6

3,080NCT01331837

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Experimental vs Placebo: deaths from any cause2 of 1,541

1 of 1,536

0.1 points

-0.3 to 0.4

3,077NCT05281094

Efficacy and Safety of Two Doses of HIL-214 in Children

Experimental vs Placebo: serious adverse events169 of 1,541

165 of 1,536

0.2 points

-2.0 to 2.4

3,077NCT05281094

Efficacy and Safety of Two Doses of HIL-214 in Children

Low-dose CT vs Standard-dose CT: Number of Negative Appendectomies22 of 1,535

16 of 1,539

0.4 points

-0.4 to 1.2

3,074NCT01925014

Low vs. Standard Dose CT for Appendicitis Trial

Low-dose CT vs Standard-dose CT: Number of Appendectomies559 of 1,535

601 of 1,539

-2.6 points

-6.1 to 0.8

3,074NCT01925014

Low vs. Standard Dose CT for Appendicitis Trial

Low-dose CT vs Standard-dose CT: Prevalence of Perforated Appendicitis182 of 1,535

176 of 1,539

0.4 points

-1.9 to 2.7

3,074NCT01925014

Low vs. Standard Dose CT for Appendicitis Trial

Low-dose CT vs Standard-dose CT: Prevalence of Non-perforated Appendicitis342 of 1,535

388 of 1,539

-2.9 points

-5.9 to 0.1

3,074NCT01925014

Low vs. Standard Dose CT for Appendicitis Trial

Low-dose CT vs Standard-dose CT: Need for Additional Imaging Test(s)39 of 1,535

41 of 1,539

-0.1 points

-1.3 to 1.0

3,074NCT01925014

Low vs. Standard Dose CT for Appendicitis Trial

Low-dose CT vs Standard-dose CT: serious adverse events43 of 1,535

40 of 1,539

0.2 points

-1.0 to 1.4

3,074NCT01925014

Low vs. Standard Dose CT for Appendicitis Trial

Patient Directed Standard of Care vs Enhanced Standard of Care: Completion of Pre-test Genetic Counseling From Electronic Health Record400 of 1,554

361 of 1,519

2.0 points

-1.1 to 5.0

3,073NCT03985852

Broadening the Reach, Impact, and Delivery of Genetic Services

Patient Directed Standard of Care vs Enhanced Standard of Care: Completion of Genetic Testing From Electronic Health Record191 of 1,554

206 of 1,519

-1.3 points

-3.7 to 1.1

3,073NCT03985852

Broadening the Reach, Impact, and Delivery of Genetic Services

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants With Statin Addition at 12 Months162 of 1,648

151 of 1,423

-0.8 points

-3.0 to 1.4

3,071NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Best Practice Clinic-Based Care vs Telehealth Care: deaths from any cause42 of 1,648

43 of 1,423

-0.5 points

-1.7 to 0.7

3,071NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Group 1: Tamoxifen + Anastrozole Placebo vs Group 2: Anastrazole + Tamoxifen Placebo: serious adverse events73 of 1,535

62 of 1,535

0.7 points

-0.7 to 2.2

3,070NCT00053898

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=124"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=124

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03467425-sae",
        "title": "FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI vs Non-Ellipta MITT: serious adverse events",
        "summary": "114 of 1545 against 114 of 1547; risk difference 0.0 points, 95% interval -1.8 to 1.9; NCT03467425, INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design",
        "record": "/library/comparisons/NCT03467425-sae",
        "nct_id": "NCT03467425",
        "kind": "serious-adverse-events",
        "participants": 3092,
        "risk_difference": {
          "value": 0.00009539289950483143,
          "lower": -0.01842451337196715,
          "upper": 0.018618733630048553
        },
        "group_1": "114 of 1,545",
        "group_2": "114 of 1,547",
        "difference": "0.0 points",
        "interval": "-1.8 to 1.9",
        "trial_title": "INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design"
      },
      {
        "id": "NCT02388165-0be3c845",
        "title": "Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days After Spinal Surgery",
        "summary": "14 of 1544 against 14 of 1547; risk difference 0.0 points, 95% interval -0.7 to 0.7; NCT02388165, Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation",
        "record": "/library/comparisons/NCT02388165-0be3c845",
        "nct_id": "NCT02388165",
        "kind": "outcome",
        "participants": 3091,
        "risk_difference": {
          "value": 0.000017583757297257724,
          "lower": -0.007081318114090713,
          "upper": 0.007122879660006014
        },
        "group_1": "14 of 1,544",
        "group_2": "14 of 1,547",
        "difference": "0.0 points",
        "interval": "-0.7 to 0.7",
        "trial_title": "Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=125",
  "request_id": "7k4kMM_rQmXgTEea"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?